Introduction and Objective: Glycemic control in diabetes can differ from person to person and automated insulin delivery (AID) with frequent autocorrections provides more personalized diabetes management. The present study assessed glycemic outcomes and insulin use of MiniMed™ 780G system (MM780G) users with different daily carbohydrate intake.Methods: CareLink™ personal data (as of October 26, 2024) of 19,286 consenting MM780G users (18-80yrs) in the United States (US) who had ≥10 days of sensor use and used recommended optimal settings (ROS, 100 mg/dL glucose target [GT] and 2 hours active insulin time [AIT]) ≥95% of the time were analyzed. Glycemic metrics including time in 70-140 mg/dL (TITR), in 70-180 mg/dL (TIR), below 70 mg/dL and above 180 mg/dL range and insulin use were stratified by quartiles of daily announced CHO.Results: Across increased daily CHO, the total daily dose of insulin (TDD), total bolus and number of CHO entries were greater, while autocorrection insulin (as %TDD) was less (Figure). The highest quartile had the highest mean TITR (57.2%), TIR (81.6%) and insulin-to-carb ratio (8.8±4.6), while the converse was observed for the lowest quartile.Conclusion: Regardless of CHO intake, a majority of MM780G users in the US with ROS achieved consensus-recommended glycemic goals. The MM780G’s unique algorithm permits adaptation to different CHO intake of people with diabetes.
R.A. Vigersky: Employee; Medtronic. Z. Dai: Employee; Metronics. F. Niu: None. J. Shin: Employee; Medtronic. T.L. Cordero: Employee; Medtronic. J.J.F. McVean: Employee; Medtronic.
Source link
Leave a Reply